Procter & Gamble Health Share Price Live

Merck Ltd is an Indian-based company. The company is the supplier of Pharmaceutical Chemicals, Formulated Chemical Products, Chemicals, Industrial Chemicals, Chemicals, Pharmaceutical Industry, and Chemical Products. They are engaged in the production and sale of pharmaceuticals and chemicals in India. The company offer prescription drugs, biotechnology products, and consumer health products, including over-the-counter products. They also offer products for the treatment of cancer, neurodegenerative diseases, infertility, endocrine and metabolic disorders, cardiovascular diseases, and other conditions with unmet medical needs. The company operates in two business divisions, namely Pharmaceuticals and Chemicals. The Pharmaceuticals business comprises of Ethicals used in the treatment of Cardiovascular and Metabolic diseases & Vitamin-based formulations and Consumer Health Care Products. The Chemicals business comprises of Bulk Drugs and Pigments. Segment revenue relating to the Chemicals business consists of bulk drugs, pigments and active pharmaceutical ingredients. Merck Ltd was incorporated in the year 1967 as E Merck (India) Ltd. The company was set up to take over the business of the Indian branch of Emeda Exports with all their assets and liabilities. The company is a 51% subsidiary of German firm Merck KGaA, is a leading player in vitamin formulations. The company started their operations as a manufacturer of pharmaceutical specialties and over the years, they have diversified their product range to include basic drugs, fine and industrial chemicals, and diagnostics. In the year 1981, the company became a public limited company they were the first in the Merck group. In December 2000, the company acquired the Livogen brand from Glaxo India for a consideration of Rs 8 crore. They entered into a co-marketing tie-up with the domestic Pharma company Kopran for a new anti-inflammatory drug Rofecoxib, in the country. They launched new drug under the brand name of 'Acrobat', while Kopran launched the product under the brand name of 'Ziflam'. In the year 2002, the company launched Anti-diabetic molecule, namely 'Glimepiride' in the market. They changed their name from E Merck (India) Ltd to Merck Ltd with effect from March 27, 2002 in order to create one strong international Merck brand and to develop a uniform international image. In the year 2004, the company sold their Taloja undertaking to Biochem Pharmaceutical Industries Ltd for a consideration of Rs 100 million. In addition, the Pharma section of the company started a new unit, namely Consumer Health Care to market medicines for common ailments. In the same year, the company formed a Public Charitable Trust known as 'Merck India Charitable Trust' with the main object of rendering financial assistance to children from the poorer section of society, to pursue primary and secondary education. In the year 2005, the company increased the production capacity of Bulk Drugs by 18 tonnes to 318 tonnes. They launched a new product, namely Pedimune, which is a formulation to improve the immunity level of Children. In the year 2006, the company expanded the production capacity of Bulk Drugs by 33 tonnes to 351 tonnes. In April 2006, the Life Science and Analytics (excluding Bulk Drugs) Business (LS&A business) of the Division was sold to Merck Specialities Pvt Ltd. All the assets and rights on the manufacturing and distribution facilities were transferred to Merck Specialities Pvt Ltd. In the year 2007, the company increased the production capacity of Injection/ Nasal Drops by 24 kilolitres to 427 kiloliters. The Pharmaceuticals segments launched Olmighty Tablets, Evion Forte Tablets, Polybion Complete Syrup, Met Neurobion Injection, Livogen CZ Tablets and Nasivion Care Drops. In the year 2008, the company expanded the production capacity of Bulk Drugs by 128 tonnes to 479 tonnes, Injection/ Nasal Drops by 13 kiloliters to 440 kiloliters and Tablets/ Capsules by 40 million Nos to 400 million Nos. In addition, they commissioned the project for the substantial expansion of the production capacity of their patented molecule, Oxynex ST. This plant is a 100% export-oriented unit and having a capacity to produce around 150 tonnes per year.